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Abstract
Background: The time necessary for malaria parasite to re-appear in the blood following treatment (re-infection time)
is an indirect method for evaluating the immune defences operating against pre-erythrocytic and early erythrocytic
malaria stages. Few longitudinal data are available in populations in whom malaria transmission level had also been
measured.
Methods: One hundred and ten individuals from the village of Ndiop (Senegal), aged between one and 72 years, were
cured of malaria by quinine (25 mg/day oral Quinimax™ in three equal daily doses, for seven days). Thereafter, thick
blood films were examined to detect the reappearance of Plasmodium falciparum every week, for 11 weeks after
treatment. Malaria transmission was simultaneously measured weekly by night collection of biting mosquitoes.
Results: Malaria transmission was on average 15.3 infective bites per person during the 77 days follow up. The median
reappearance time for the whole study population was 46.8 days, whereas individuals would have received an average
one infective bite every 5 days. At the end of the follow-up, after 77 days, 103 of the 110 individuals (93.6%; CI 95% [89.0–
98.2]) had been re-infected with P. falciparum. The median reappearance time ('re-positivation') was longer in subjects
with patent parasitaemia at enrolment than in parasitologically-negative individuals (58 days vs. 45.9; p = 0.03) and in
adults > 30 years than in younger subjects (58.6 days vs. 42.7; p = 0.0002). In a multivariate Cox PH model controlling
for the sickle cell trait, G6PD deficiency and the type of habitat, the presence of parasitaemia at enrolment and age ≥ 30
years were independently predictive of a reduced risk of re-infection (PH = 0.5 [95% CI: 0.3–0.9] and 0.4; [95% CI: 0.2–
0.6] respectively).
Conclusion: Results indicate the existence of a substantial resistance to sporozoites inoculations, but which was
ultimately overcome in almost every individual after 2 1/2 months of natural challenges. Such a study design and the
results obtained suggest that, despite a small sample size, this approach can contribute to assess the impact of
intervention methods, such as the efficacy vector-control measures or of malaria pre-erythrocytic stages vaccines.
Published: 15 July 2009
Malaria Journal 2009, 8:161 doi:10.1186/1475-2875-8-161
Received: 9 June 2009
Accepted: 15 July 2009
This article is available from: http://www.malariajournal.com/content/8/1/161
© 2009 Tall et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2009, 8:161 http://www.malariajournal.com/content/8/1/161
Page 2 of 8
(page number not for citation purposes)
Background
Exposure to parasites induces immune responses, which
can reduce parasite loads. The acquisition of a state of pro-
tection against clinical malaria, called premunition, by
individuals who are regularly infected with Plasmodium
falciparum enables them to control parasite densities to
low levels and, thereby, to reduce the incidence of clinical
malaria episodes. This control is usually considered to be
mainly induced by and effective against erythrocytic
forms of P. falciparum [1]. However, it has been proposed
that the protection acquired by exposure to infection, may
also extend to other stages including pre-erythrocytic
forms [2]. Experimental studies have shown that exposure
to irradiated sporozoites induces parasitological and clin-
ical immunity[2]. In natural conditions, exposure to
infected mosquitoe bites induces immune responses to
sporozoite surface antigens and their intensity is a func-
tion of the Entomological Inoculation Rate (EIR), and,
obviously, of age, reflecting the cumulative number of
sporozoites received [3-6]. Naturally acquired antibodies
also strongly inhibit sporozoite invasion into hepatocytes
under in vitro conditions [7].
This exposure-induced immunity may explain why in
many hyperendemic areas the incidence of malaria attacks
is always markedly lower than predicted by the number of
sporozoite inoculations. For instance, 1–5 malaria
attacks/child/year are observed in areas where children
receive >100 infective inocula by mosquitoes per year
[8,9], suggesting a reduction of the proportion of inocu-
lum that leads to a blood parasitaemia proportional to the
antigenic natural stimulation by pre-erythrocytic stages of
the parasites. However, as the evaluation of immunity is
based on the detection of blood parasitaemia, it is difficult
in observational studies to distinguish the respective
effects of immune responses against pre-erythrocytic and
erythrocytic stages. Several studies have attempted to doc-
ument the existence of a pre-erythrocytic "brake" [9],
which may result from immunity acquired by exposure to
antigens from sporozoites and liver stages. It has been
shown for instance that a tenfold decrease in malaria
transmission is associated, with only a two-fold decrease
in malaria morbidity [9] and little changes in parasitae-
mia. In the Garki project, it proved impossible to make a
transmission model fit field observations, unless a strong
density-dependent pre-erythrocytic filter, or brake, was
assumed [8].
One way of quantifying this control of new malarial inoc-
ulations, is to measure the time of reappearance of blood
parasites in subjects whose parasitaemia has been cleared
by radical cure and who are exposed to measured num-
bers of infective mosquitoe bites (called 're-positivation'
here), i.e. to measure the relative success of new sporo-
zoite inoculations [8,10-12]. This method, which is rec-
ommended by WHO in the field to test the efficacy of
candidate vaccines, has been previously used [13].
In the present study, the relationships between the re-
infection time and several host factors were analysed in a
Senegalese community living in the village of Ndiop, an
area of seasonal malaria transmission. The aim was to
identify the host factors involved in this immune resist-
ance or the factors that could serve as intermediate criteria
for the evaluation of intervention methods.
Methods
Follow-up procedure
The existing set-up of Ndiop, a village of about 350 inhab-
itants, located in the Sine-Saloum, in the sahelo-sudanian
region of Senegal, was used. In this village, numerous
malaria studies, particularly extremely close monitoring
of clinical malaria attacks (daily active case detection),
drug use and entomological follow-up have been in place
since 1993, according a protocol that was identical to that
used in the village of Dielmo, Senegal. Thick blood smears
were prepared Giemsa-stained, and examined by 1,000×
light microscopy using oil immersion. Parasitaemias were
scored per microliter of blood by counting the number of
asexual parasites per 100 white blood cells, assuming
8,000 blood cells per microliter, and multiplying the par-
asite count by 80 [14]. Malaria transmission is seasonal
from July to October. Malaria vectors are Anopheles arabi-
ensis, Anopheles gambiae and Anopheles funestus [15]. Bio-
logical tests, including haemoglobin electrophoresis and
tests for glucose-6-phosphate dehydrogenase (G6PD)
deficiency, were available for most subjects participating
in the study. The type of habitat and bed net use were
recorded for each subject. One hundred eighteen volun-
teers, aged one year or above, were enrolled in the study at
the end of the dry season (in August, 1997). During the
study period, treatment relied on the administration of
quinine chlorhydrate (Quinimax®, Sanofi-Synthelabo,
France), chosen in view of its efficacy in this area of chlo-
roquine resistance, of its fast effect, and its short half-life.
It was administered orally at a dose of 8 mg/kg under
medical supervision (with assessment of proper inges-
tion) at 8 h intervals (i.e., 25 mg/kg/d) for 7 d. The very
short half-life of quinine has the advantage to avoid the
persistence of prophylactic concentrations of the drug in
the receivers' blood that could provide artificial protection
in the following weeks or months, i.e., avoid introducing
a confounding factor as compared to other antimalarial
drugs. Since free medical care is available 24 h/d, self-
treatment is known to be most uncommon, as ascertained
by systematic detection of anti-malarial drugs [16]. In case
of systemic adverse events (including fever, headache,
nausea, vomiting and asthaenia), the subject was
excluded from the study. After seven days of quinine treat-
ment, the thick blood smears of all the participantsMalaria Journal 2009, 8:161 http://www.malariajournal.com/content/8/1/161
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proved to be negative. Thick blood smears were examined
every week for 77 days or until reappearance of a patent
asexual P. falciparum parasitaemia or loss to follow-up
(missing two consecutive thick blood smears). The para-
site reappearance time was defined as the number of days
between the end of quinine treatment and the detection
of P. falciparum on blood films.
Informed consent was first obtained at community level.
The informed consent of each villager (or that of the par-
ents in the case of children) was orally obtained at the
beginning of the study after a thorough explanation of its
purpose and was renewed at each stage of the survey. The
study design received clearance from the Senegal National
Ethics Committee (Dakar, Senegal) [17].
Entomological survey
Night captures using human bait were conducted indoors
and outdoors every Monday and Thursday night during
the whole study period. The mosquitoes were captured
from 9:00 PM until 7:00 AM by four groups of two collec-
tors (two indoors and two outdoors), with each collector
alternatively working and resting for 1 hr. The field and
laboratory processing have been described previously
[15].
Statistical analysis
Differences in reappearance rate of patent Plasmodium par-
asitaemia related with epidemiological and genetic varia-
bles were tested using log-rank test (bivariate analysis)
and Cox model (multivariate analysis). The BMDP 7.0
(Statistical Software, Inc., Los Angeles, CA) and SPIDA
(Statistical Computing Laboratory, Eastwood, Australia)
software packages were used for analysis. Due to the rela-
tive small size of the cohort, results could not be analysed
for each age group, but the population was divided in two
groups below or above 30 years. This cut-off value was
defined by using the Akaike index for age either consid-
ered as a continuous variable or for various dichotomous
variables (i.e. 1–9,1,10–19,20–30, >30, >40 years etc),
and choosing the best fit [18].
Results
One hundred eighteen persons were included and treated
(114 for seven days and four for six days or less). Of the
114 persons who had received the full course of treat-
ment, four left the village during the first week of follow-
up period and were therefore excluded. A total of 110 sub-
jects (46 M/64 F; median age [min-max]: 13.9 [1.2–72])
were monitored during the eleven weeks follow-up period
and were included in the analysis. Three individuals
missed two consecutive thick blood smears on the 7th,
42nd and 57th day respectively. Four individuals (3.6%)
used a non-impregnated bed net. Before treatment, the
prevalence of P. falciparum asexual blood infection was
21.4% (6/28) among subjects ≥ 30 years old versus 10.9%
(9/82) in subjects < 30 years old (NS). The prevalence of
patent parasitaemia did not differ according to whether an
anti-malarial cure had been received during the year pre-
ceding the study or according to the time between the pre-
vious treatment and the beginning of the study.
Seven hundred forty (740) malaria vectors were captured
during 128 person-night collections on human volunteers
during the four-month study period, and their salivary
glands examined. The resulting EIR was 15.3 infective
bites per person during the 77 days follow up period.
Reappearance time
Two individuals were infected with Plasmodium ovale: a
13-year old on day 71 and a 38-year old on day 76. Two
other individuals were infected with Plasmodium malariae
– two children aged 9 and 11 on day 29 and 70, respec-
tively. The following results only concern P. falciparum
infections.
The results (Figure 1 and Table 1) show that sporozoite
inoculations occurring on average every five days did not
each led to a patent parasitaemia. Indeed, it took more
than one month to detect parasites reappearing in only
25% of the exposed population and about 50 days (corre-
sponding to an average 10 infective bites) or only half of
the population to become positive again. The median re-
appearance time for the whole human population was
46.8 days. Nevertheless, at the end of the follow-up, after
77 days, the majority, 103 persons (93.6%; CI 95% [89.0–
98.2]) had been re-infected with P. falciparum, as defined
by: i) the documented clearance of parasitaemia after
seven days quinine treatment and; ii) the detection of P.
falciparum  on thick blood smear during the follow-up.
Among the seven persons without reappearance of P. fal-
ciparum  blood parasitaemia, five subjects were over 30
years old. Conversely, the shortest reappearance time was
seven days and was observed in an 8-years-old child.
Bivariate analysis
Bivariate analysis led to two main observations: the
median reappearance time was found to be significantly
longer i) in subjects having a patent P. falciparum parasi-
taemia at the time of enrolment than in parasitologically-
negative individuals, and ii) in adults over 30 years as
compared to younger subjects (58 days vs. 45.9; p = 0.03
and 58.6 days vs. 42.7; p = 0.0002 respectively) (Figure 1).
Importantly, other parameters, such as the type of hous-
ing, the gender and the G6PD deficiency, were not associ-
ated with the time to re-infection, and individuals with
the sickle cell trait demonstrated a non-significant trend
to an extended time to reappearance (Table 1).Malaria Journal 2009, 8:161 http://www.malariajournal.com/content/8/1/161
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Multivariate analysis
A multivariate Cox proportional hazards model including
age, prior parasitaemia, sickle cell trait, space between the
roof and the wall of the house revealed that only age ≥ 30
years and parasitaemia prior to treatment were independ-
ently associated with partial protection from reinfection.
The Cox PH was 0.5 [95% CI: 0.3–0.9] for age (age < 30
years as reference group) and 0.4 [95% CI: 0.2–0.6] for
prior parasitaemia (clinically non-patent parasitaemia at
inclusion as reference group). Using different cut-of val-
ues than 30 years also led to conclude about the role of
age, but in less significant manner.
Discussion
In this medium-low transmission area, reinfection studies
show a substantial resistance of individuals to sporozoite
inoculations. Indeed it required an estimated average of
more than six inoculations of sporozoites to positivate 25
percent of the population and more than 10 to positivate
half of the cohort. However, after an average of 15 infec-
tive bites, all but seven individuals had been undergoing
a successful liver schizogony, as shown by patent blood
infection. Similar resistance to sporozoite inoculations
has already been reported in individuals exposed to both
high and low transmission conditions in Senegal, such as
in Dielmo, with average 200 infective bites/person/year
[19] and in Diohine, with 10 infective bites/person/year
[20]. In Dielmo, the median times before reappearance of
P. falciparum were 22, 39, and 53 days among age-groups
1–6, 7–14, and ≥ 15 years, respectively, i.e. confirming the
strong effect of age, and showing long positivation delays
in adults. After 98 days of follow up, corresponding to an
average 35 infective bites, 12% of the population had not
been yet become positive again, showing a stronger level
of resistance to blood positivation than in Ndiop. In Dio-
hine, the median time to reappearance of P. falciparum
Cumulative incidence of asexual Plasmodium falciparum parasitaemia as a function of time after treatment according to age  group Figure 1
Cumulative incidence of asexual Plasmodium falciparum parasitaemia as a function of time after treatment 
according to age group.Malaria Journal 2009, 8:161 http://www.malariajournal.com/content/8/1/161
Page 5 of 8
(page number not for citation purposes)
was 28 days in individuals < 40 years[20]. Similar studies
were conducted in the villages of Sotuba (Mali) and in
Saradidi (Kenya) respectively, areas of low and high trans-
mission conditions. In Sotuba (Mali), the maximal rein-
fection rates were observed between 7 and 9 weeks post
treatment; 60 of the 88 reinfections occurred during this
time period. In these two studies, the analysis was
restricted respectively to individuals less than twenty of
age and in infants aged from 6 months to 6 years [21,22],
whereas in the present study the number of individuals
was larger and they belonged to all age groups. In Nav-
rongo (Ghana), where malaria transmission is intense
[23], the first infections were identified during week 3 of
post-cure follow-up, the majority of new infections
occurred during weeks 5–10. Here as well, 98% had
finally become positive again, however only after a long
delay of five months of exposure [23]. Results obtained in
the very high transmission area of Idete (Tanzania),
although gathered by different methods, concur to the
same conclusions[24]. The EIR of 1.6 (+ 2.1) per person,
per day, were much higher than the corresponding blood
infection rates. The seasonal increase in EIR (> 4/night)
was not accompanied by an increase in new blood infec-
tions. Results show that 93% and 99.6% of sporozoite
inoculations in low and high season respectively, were
blocked, i.e. did not result in a detectable blood infection,
showing the acquisition of an extremely strong pre-eryth-
rocytic or/and early erythrocytic "brake" under high trans-
mission conditions.
The reappearance time was longer in subjects with parasi-
taemia upon enrolment than in individuals without,
independently of age or administration of antimalarial
treatment over the year preceding the study. This result is
in apparent contradiction with that recorded in the higher
endemic area of Dielmo, where previous parasitaemia was
associated with an increased risk of the patient becoming
prositive again [19]. However, this observation should be
interpreted in the context of differences in anti-blood
stage immunity. Indeed, in Ndiop, the clinically non-pat-
ent parasitaemia before cure, observed in only 15 individ-
uals, was made of very low parasite densities: 70% had a
parasitaemia of less than eight trophozoites per μl. In
Dielmo, where transmission is continuous with higher
prevalence and higher loads of parasites, the results
should be analysed separately for either low or high pre-
Table 1: Reappearance time of asexual P. falciparum parasitaemia according to variables (log-rank test)
Reappearance time of P. falciparum (days)
n 25% 50% 75% p-value
Parasitaemia before treatment
no 94 33.0 45.9 57.2 0.0338
yes 15 44.1 58.0 73.9
Age
< 30 years 82 30.7 42.7 53.5 0.0002
≥ 30 years 28 50.4 58.6 68.6
Gender
Female 64 33.0 48.1 58.2 0.9646
Male 46 35.0 46.4 59.8
Haemoglobin
AA 81 31.5 45.2 57.8 0.2486
AS 29 40.2 51.1 61.0
G6PD
< 6.9 μI 12 35.3 48.1 58.9 0.7743
≥ 6.9 μI9 2 3 1 . 5 4 5 . 2 5 9 . 7
Roof of the hut
thatched 74 33.2 48.8 58.5 0.5687
zinc 36 33.6 46.5 58.9
Wall of the hut
cement 91 32.4 48.6 59.3 0.2821
banco 19 36.3 44.1 57.7
Free space between roof and wall
present 74 32.2 45.8 58.3 0.1910
absent 36 34.6 49.9 60.2
* values are the number of days until 25 or 50 or 75% of the studied population was reinfected.Malaria Journal 2009, 8:161 http://www.malariajournal.com/content/8/1/161
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existing parasitaemia. Among the subset of individuals
with only low circulating parasitsemia, the reappearance
time was also longer, i.e. results are consistent with those
observed in Ndiop. In the remaining, with higher initial
parasite loads, the susceptibility to sporozoite inoculation
increased: an increase of 1,000 trophozoites per μl was
significantly associated with an increased risk of positiva-
tion by 1.6 [1.2–2.1]. The reasons for this opposite behav-
iour and effect upon re-positivation are not known A
possible explanation is that the high parasitaemia, which
are known to induce an immune suppression[25],
decreased acquired defences against the sporozoite stage.
Age was significantly associated with reappearance time in
all studies. However, the age at which the risk of reappear-
ance of parasitaemia decreased significantly varied
according to the studies and was grossly in relation with
transmission intensity, i.e. in relation with exposure to
sporozoites and hence potentially to anti-sporozoite
immunity. It was significant in individuals > 40 years in
Diohine [20], where the level of transmission is low, in
individuals > 30 years in the present study, and in individ-
uals > 7 years in Dielmo where the transmission is highest
[19]. In Sotuba, the same age trend was observed but it
was not significant most likely because of the limited age
range of the study population [21]. In other words, indi-
viduals acquired faster resistance to reinfection in areas of
high transmission, such as Dielmo, than in moderate
areas of transmission, such as in Ndiop, or than in areas
of low transmission, such as Diohine. This relationship
suggests that exposure to higher numbers of sporozoites
in areas of high transmission induces a stronger pre-eryth-
rocytic immunity than in areas of moderate or low trans-
mission, i.e. bring support to the concept of sporozoite
exposure-dependant immunity. In contrast, the relative
success of sporozoite inoculations is maximal in naïve
non-immune individuals, as shown by blood parasitae-
mia induced in volunteers exposed to two infected mos-
quitoe bites [26], and decreases in malaria-endemic areas,
as a function of EIR and age, ie of exposure to sporozoites.
Similar findings have been reported for other stages such
as gametocytes, with evidence for gamete-blocking anti-
bodies. Thus exposure to various stages of the parasite life
cycle, sporozoite, liver stages, asexual blood stages, game-
tocytes, would generate a parasite-dependent, stage-spe-
cific immunity that modulate the survival of the
corresponding stage. The lack of significant effect of the
sickle cell trait upon the time it takes for a patient to
become positive again may be significant in that respect.
As sickle cell trait is the strongest known factor of protec-
tion against erythrocytic stages, this observation brings
support to the view that re-positivation studies measures
mostly pre-erythrocytic immune defences. Indeed, in the
same community, the well-documented strong effect of
the sickle cell trait against clinical malaria, including
uncomplicated clinical malaria, was confirmed [27], and
this effect has been consistently reported elsewhere
[28,29]. Thus immunity against each stage can be distin-
guished by distinct features. The sickle cell phenotype
does not prevent blood infection, but merely reduces
blood parasite densities and thereby prevents symptoms.
Indeed, it is well-documented that, in hyperendemic Afri-
can settings, a majority of individuals carry parasites.
However pathological manifestations occur only when
parasite densities in the blood are high, a phenomenon
which led to define a parasite density threshold to
attribute fever to malaria [30,31]. Blood stage anti-para-
site immunity prevents symptoms, not infection. In con-
trast pre-erythrocytic stage immunity prevents infection,
regardless of whether the breakthrough parasite reach, or
not, a clinical patency threshold of density. Indeed in this,
as in previous studies of re-positivation, the emergence of
new parasites in the blood did not required treatment in
the majority of cases, as pre-existing blood stage immu-
nity controlled parasite loads below the pathogenic
threshold. Together this suggests also that AS phenotype
or anti-erythrocytic stages immunity modulates parasite
densities, whereas pre-erythrocytic immunity modulates
the emergence of new blood infections following expo-
sure to sporozoite inoculations. Understandably both
types of immunity are related to previous exposure to each
stage and hence to age, as described above. The occurrence
of clinical malaria corresponds to the lack of ability to
control the parasite at each stage, and conversely resist-
ance is likely dependant on the sum of these two immu-
nities. Additional studies are required to better identify
the role of each.
Conclusion
Results obtained in this and in previous studies bring sup-
port to the existence of a resistance to sporozoite inocula-
tion which increases, as a function of parasite
transmission levels and age, i.e. depending on previous
exposure to pre-erythrocytic stages. Further similar studies
are required to better delineate the part related to pre-
erythrocytic and to erythrocytic stages immune responses.
Indeed, several malaria control measures are targeted
against the pre-erythrocytic phase of the cycle, such as vec-
tor-control measures, i.e. intra-domiciliary spraying,
insecticide-impregnated curtains or bed nets, repellents,
and experimental vaccines directed against the sporozoite
and/or liver stages, the impact of which would be best
evaluated using stage-specific tools. The design and results
of re-positivation studies indicate that they can contribute
to monitor the efficacy of those interventions.
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